19P Stock Chart & Stats
€7.70
€1.20(4.76%)
At close: 4:00 PM EST
€7.70
€1.20(4.76%)
Day’s Range― - ―
52-Week Range€6.85 - €27.48
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€591.22M
Enterprise Value€595.79M
Total Cash (Recent Filing)€74.71M
Total Debt (Recent Filing)€92.56M
Price to Earnings (P/E)71.9
Beta0.31
Next Earnings
Sep 09, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding61,811,890
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.13Price Target Upside57.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)0.35
Revenue Forecast (FY)€444.21M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And FCF GrowthPhreesia has moved from prior negative cash years to consistent cash conversion: TTM OCF and FCF levels and ~19% FCF growth provide durable internal funding for operations, tuck-in M&A, and debt servicing. Sustained FCF reduces dependence on equity raises and strengthens financial flexibility over months.
Profitability Inflection And Improved MarginsThree consecutive profitable quarters and materially higher adjusted EBITDA margins signal structural cost discipline and scalable unit economics. If management sustains margin expansion and keeps cost initiatives, the company can convert revenue growth into durable earnings and reinvestment capacity over 2–6 months.
Enhanced Liquidity And Financing FlexibilityRefinancing the bridge with a multi-year revolver and expanding the securitization facility materially boosts liquidity and funding optionality for Payment Solutions and Access One. This structural funding improvement supports growth and lowers near-term refinancing risk, enabling stable operations and execution of strategic initiatives.
Bears Say
Sequential Subscription Revenue DeclineSubscription revenue underpins recurring economics; a sequential ~6% decline—partly from deliberate pricing moderation—signals potential erosion of the core recurring base or muted pricing power. Over months this can limit durable revenue visibility and reduce upside from cross-sell unless retention and pricing strategies stabilize.
Visibility And Variability In Network Solutions DemandGreater client-level variability and lower second-half commitments reduce topline predictability and can impair capacity planning and margin optimization. Structural uncertainty in Network Solutions revenue could force conservative guidance or require higher sales/marketing investment to secure commitments, pressuring medium-term growth.
Acquisition-driven Payment Growth And Higher Receivables Concentration RiskPart of Payment Solutions expansion reflects inorganic contribution from Access One, which raises integration and sustainability risk for organic growth. The amended securitization increases concentration limits and makes Phreesia a co-guarantor, increasing credit exposure and potential balance sheet volatility if higher-risk receivables underperform.
Phreesia News
19P FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was €6.85 and its highest was €27.48 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is €591.22M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Sep 09, 2026 which is in 68 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on May 27, 2026. The company reported €0.044 earnings per share for the quarter, beating the consensus estimate of €0.01 by €0.034.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.07.
How many shares outstanding does Phreesia have?
Phreesia has 61,811,890 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of €0.044 in its last earnings report, beating expectations of €0.01. Following the earnings report the stock price went up 21.053%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in DE:19P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€12.13 (57.53% Upside)
€12.13 (57.53% Upside)
Blogger Sentiment
Neutral
DE:19P Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €9.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.37%
12-Months-Change
Fundamentals
Return on Equity
2.79%
Trailing 12-Months
Asset Growth
66.37%
Trailing 12-Months
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
19P Company Deck
19P Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear operating and financial positives: solid top-line growth (+13% YoY), strong adjusted EBITDA improvement (+~46% YoY) and a return to net income, improved operating and free cash flow, enhanced liquidity via refinancing and a larger securitization facility for Access One, and maintained full-year guidance. Headwinds included a sequential decline in subscription revenue, higher variability and lower-than-expected client commitments in Network Solutions for the back half of the year, and some dependence of Payment Solutions growth on the recent Access One acquisition. On balance, the positive operational and financial momentum, maintaining guidance, and strategic financing and product initiatives outweigh the listed challenges.View all DE:19P earnings summaries19P Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
19P Stock 12 Month Forecast
Average Price Target
€12.13
▲(57.53% Upside)
Technical Analysis
Options Prices
Currently, No data available
---